SOLICITATION NOTICE
99 -- 99-PCR Products
- Notice Date
- 5/6/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20042-NQ
- Response Due
- 5/21/2002
- Archive Date
- 6/5/2002
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov, rasmusc@mail.nih.gov
- Description
- The National Cancer Institute(NCI), Center for Cancer Research(CCR) plans to enter into a sole source contract with Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304, to acquire one set of Human Unigene I Easy to Spot PCR Products. Incyte is the only provider of this unique set. the Center for Cancer Research maintains a state-of-the-art facility for the production of gene microarrays. The microarrays allow researchers to study simultaneously by differential expression of large numbers of cancer genes in normal and diseased or treated cells. The CCR Microarray Facility uses modern lab automation and robotic methods to "print" these arrays by spotting small volumes of prepared cDNA clones (PCR products) at specific locations on specially prepared glass slides. (PCR products of cDNA clones from multiple thousands of genes can localized to a small glass slide. The composition of the PCR sets and quality controls used in their manufacture are critically important for the continuation of existing experimental protocols and standards. The NCI/CCR Microarray facility has ongoing projects utilizing Incyte products previously, having produced thousands of microarrays which are in use by intramural investigators and the NIH MouseModels of Human Diseases Consortium. An important aspect is that the clones are not full-length copies of the genes of interest, but are biased towards the 3' end of the gene. In pratical terms, this means that clone from the same genes, but generated from other vendors, will have a different composition. It is critical for experimental continuity and reproducibility that the NCI/CCR continue to acquire from this source. Incyte Genomics Inc., is the only company known to the Government that can meet the required specifications. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. Capability statement and any other furnished information must be in writing and must contain sufficient material to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:30 PM EST (local Washington, DC time) on May 21, 2002. This action is pursuant to 41 USC 253(1) and under the authority of FAR 6.302-1. If you have any questions, please contact Cynthia Brown, Purchasing Agent on (301) 402-509. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NAICS Code 325413.
- Record
- SN00072031-W 20020508/020506213208 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |